Home » Stocks » CytoSorbents

CytoSorbents Corporation (CTSO)

Stock Price: $8.30 USD 0.04 (0.48%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
After-hours: $8.36 +0.06 (0.72%) Oct 23, 5:47 PM

Stock Price Chart

Key Info

Market Cap 358.21M
Revenue (ttm) 32.03M
Net Income (ttm) -17.15M
Shares Out 43.16M
EPS (ttm) -0.51
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $8.30
Previous Close $8.26
Change ($) 0.04
Change (%) 0.48%
Day's Open 8.28
Day's Range 8.17 - 8.39
Day's Volume 116,079
52-Week Range 3.49 - 11.74

More Stats

Market Cap 358.21M
Enterprise Value 339.04M
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 43.16M
Float 38.26M
EPS (basic) -0.51
EPS (diluted) -0.51
FCF / Share -0.31
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.99M
Short Ratio 8.45
Short % of Float 7.82%
Beta 0.47
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 11.18
PB Ratio 14.73
Revenue 32.03M
Operating Income -16.84M
Net Income -17.15M
Free Cash Flow -11.19M
Net Cash 19.18M
Net Cash / Share 0.44
Gross Margin 54.91%
Operating Margin -52.57%
Profit Margin -53.60%
FCF Margin -34.93%
ROA -27.07%
ROE -95.66%
ROIC -89.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (7)

Buy 7
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$14.71*
(77.23% upside)
Low
13.0
Current: $8.30
High
16.0
Target: 14.71
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue24.9522.5015.159.534.794.122.421.340.04-
Revenue Growth10.87%48.53%59.02%98.84%16.22%70.18%80.4%3622.31%--
Gross Profit17.5915.019.635.572.581.990.511.020.02-
Operating Income-18.97-15.58-9.84-11.49-9.30-6.89-4.71-3.49-4.44-2.82
Net Income-19.27-17.21-8.46-11.76-9.48-9.32-4.68-3.66-5.48-2.91
Shares Outstanding32.2630.7227.6125.4324.8914.389.447.936.413.92
Earnings Per Share-0.60-0.56-0.32-0.46-0.38-1.29-0.75-0.75-1.25-1.25
Operating Cash Flow-16.76-10.84-6.46-6.73-9.05-6.28-3.49-3.62-3.83-2.48
Capital Expenditures-0.70-0.67-0.99-0.14-0.40-0.15-0.04-0.02-0.03-0.14
Free Cash Flow-17.46-11.51-7.45-6.87-9.45-6.43-3.53-3.64-3.86-2.62
Cash & Equivalents12.2322.3717.325.257.515.552.181.731.191.06
Total Debt15.6911.019.994.91--1.640.930.571.08
Net Cash / Debt-3.4611.367.330.337.515.550.540.800.62-0.02
Assets27.3834.2024.109.6911.258.474.053.342.121.81
Liabilities23.9617.2613.848.363.044.5118.312.081.802.30
Book Value3.4216.9310.261.348.213.96-14.27-11.63-10.09-0.48
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name CytoSorbents Corporation
Country United States
Employees 156
CEO Phillip P. Chan

Stock Information

Ticker Symbol CTSO
Stock Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Unique Identifier NASDAQ: CTSO

Description

Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors; and VetResQ device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients; K+ontrol for treatment of severe hyperkalemia with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, a development-stage extracorporeal hemoperfusion cartridge designed to remove toxic chemicals from the blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to CytoSorbents Corporation in May 2010. The company was founded in 1997 and is based in Monmouth Junction, New Jersey.